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Abstract. The fascinating story of ghrelin started more than 30 years ago with the discovery of synthetic (non-
natural) growth hormone (GH) releasing peptides. Scientists were searching for a novel peptide, ligand of orphan GH 
secretagogue receptor. The discovery of ghrelin is a typical example of reverse pharmacology. The new peptide 
quickly attracted a lot of attention by its pleiotropic nature, and provoked a burst of new enthusiasm among scientists 
and clinicians. Ghrelin is mainly produced in the stomach from a distinct group of endocrine cells located within the 
gastric oxyntic mucosa. It acts as hunger signal and long-term body weight regulator. But, ghrelin is much more than 
just a natural orexigenic factor and GH secretagogue. It exerts major peripheral endocrine and non-endocrine 
actions, and it has a role in learning and memory, glucose homeostasis, immunity, cardio protection, fertility and 
addiction. Exploring the actions of ghrelin and ghrelin agonists and receptor antagonists or reverse agonists could 
establish new treatment options for so far incurable diseases. 
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Introduction 

 
The discovery of ghrelin allowed us to intrigue our stu-
dents at the very beginning of the lecture with the fact 
that even stomach has endocrine properties. 
The ghrelin-ghrelin receptor system is one of the most 
important mechanisms regulating energy balance and 
metabolism. The discovery of ghrelin in 1999 by Kojima 
group opened new era in energy homeostasis investigation 
and held the promise for new therapeutic options for a 
variety of health problems assigned as leading causes of 
morbidity and mortality all over the world [1,2]. 
Identified as a natural ligand for GHsR (Growth 
Hormone secretagogue Receptor), the small peptide 
provoked a burst of new enthusiasm among scientists and 
clinicians. 
The Precursor of ghrelin is preproghrelin which is 
consisted of 117 amino acids. Ghrelin is present in two 
formes: acylated and non- acylated, both of them with 
remarkable activity. The ghrelin O-acyltransferase enzyme 
(GOAT enzyme) is critical in switching from one form to 
another. Furthermore the mystery is even more provocative 
by discovery of obestatin as the product of the same 
ghrelin gene, with the reciprocal activity [2]. 
Ghrelin is mainly produced in the stomach from a 
distinct group of endocrine cells located within the gastric 
oxyntic mucosa. Intestinal mucosa and pancreas are also 
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capable of producing a certain amount of ghrelin. The 
expression of ghrelin within the brain, pituitary, thyroid 
gland, testis, kidney and placenta suggests the pleiotropic 
nature of ghrelin action [13]. 
Several hormones, including peptide YY, pancreatic 
polypeptide, oxyntomodulin, glucagon-like peptide-1 and 
cholecystokinin act as satiety signals. Only ghrelin, a small 
opioid peptide produced by the stomach, functions as 
putative hunger gut signal appearing to act both as meal 
initiator and a long-term body weight regulator [4]. 
Ghrelin Discovery 
Kojima et al. discovered ghrelin in 1999 as 28-amino acid 
peptide from the rat stomach extracts. Many researches 
were hunting for this hormone, but discovery took a long 
time. 
The story of ghrelin, from the initial development of an 
artificial GHS (growth hormone secretagogue) to the iden-
tification of the endogenous ligand, is a typical example of 
the general paradigm of reverse pharmacology [1]. This 
story also makes the investigators reevaluate the im-
portance of purification of natural substances. By scanning 
genomic databases, some amino acid sequences could be 
identified, but natural substances sometimes escape. 
Ghrelin is such a case. Kojima’s team had been searching 
for novel unknown peptides for almost 30 years. They 
discovered the opioid peptides (α-neoendorfin), neurome-
dins and the natriuretic peptide family. As Kojima said, it 
was very exciting to find a novel peptide and explore un-
known physiological functions. From the beginning of 
1998, they had been searching for the endogenous ligands 
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of several orphan receptors, although none of the ligands - 
except for ghrelin have yet been discovered [5]. Profes-
sional luck or intuition led Kojima to switch the search 
from brain to stomach and to make great discovery. The 
new peptide was named ghrelin according “ghre”, the 
Proto-Indo-European root of the word „grow“ [5]. 
Secretion and Receptor Distribution 
Two thirds of gastric mucosa, the epsilon cells of the 
gut and pancreas, pituitary, thyroid, kidney, lung, brain 
and even lymphocytes produce ghrelin. Secretory gran-
ules containing “X/A–like”-cells, recognized in gastric 
mucosa since 1960 are in fact ghrelin cells. They repre-
sent about 20% of the endocrine population in adult 
oxyntic glands. Ghrelin-immunoreactive cells are also 
found in the duodenum, jejunum, ileum and colon, 
gradually decreasing from duodenum to colon. Secretion 
of ghrelin has been also proven in rat hypothalamic and 
pancreatic cells [3]. The human ghrelin gene is located on 
chromosome 3p25-26. Mature ghrelin mRNA contains two 
transcripts (A and B). Translation produces ghrelin precur-
sor consisting of ghrelin (28 amino acids) and obestatin 
(117 amino acids), further exposed to cleavage and acyl 
modification. Receptors (GHsR) 1a and 1b encoded by 
gene located on 3q26.31 are widespread including tumors 
and metastases. Effects include local and systemic re-
sponses [6]. GHsR1a is G-protein coupled receptor 
(GPCR) expressed in the brain as well as other areas of the 
body. Ghrelin receptor mRNA is prominently expressed in 
the arcuate (ARC) and venromedial (VMN) and in hippo-
campus [1]. Ghrelin activation of the ghrelin receptor, 
GHs-R1a, has many regulatory effects on physiology and 
behavior, such as enhancement of memory and learning, 
neuroprotection, immune function improvement, blood 
glucose control, potentiation of food and drug addiction, 
and cardiovascular and renal protection [28]. The exist-
ence of ghrelin and its receptor in the hippocampus, a 
region associated with learning and memory, suggests the 
role of ghrelin in memory formation [1]. 
Factors Influencing Ghrelin Secretion 
Ghrelin secretion is increased by starvation, in anorexia 
nervosa, low BMI conditions, and during sleep. Leptin, 
GHRH, thyroid hormones, testosterone stimulate ghrelin 
secretion, while somatostatin, insulin, PYY and PP are 
inhibiting it. Ghrelin concentration is low in obese subjects, 
after food intake, in conditions accompanied by high 
glucose and lipid levels [15]. Stomach strech is not a 
stimulus for ghrelin inhibition which was proven by filling 
rat stomach with water after starvation. However the 
addition of dextrose did decrease ghrelin secretion, 
suggesting that hypoglycemia itself might be the stimulus 
for ghrelin release [69].  
Helicobacter pylori infection of gastric mucosa 
could have a negative impact on ghrelin production and 
secretion, but opposite results are also published [10,11]. 
Weight gain following Helicobacter pylori eradication 
may be attributable to changes in plasma and gastric 
ghrelin; however, this hypothesis needs to be further in-
vestigated [12]. 
Ghrelin Action 
Discovered as a potent GH secretagogue, ghrelin quickly 
demonstrated its pleiotropic nature. Opposite to leptin it 
stimulates food intake and rises BMI in rodents and hu-
mans (Fig 1). In fact this hormone is one of the most im-
portant factors regulating appetite and energy expenditure. 
Ghrelin is also known as starvation hormone; potent orexi-
genic signal acting via NPY/ Agouti Related Peptide 
(AGRP) and orexine neurons stimulation in nucleus arcu-
atus. Investigation of fasting and feeding on human plasma 
levels of ghrelin showed peak values after 12 hours of star-
vation, achieving sharp fall after 30 minutes of meal intake. 
Three hours later ghrelin is gradually reversed to the start-
ing peak value. Furthermore ghrelin is a trigger for other 
neuroendocrine, metabolic and nonendocrine actions [13].  
 
Fig. 1 Control of energy balance. 
Both peripheral and central administration of ghrelin 
potently promotes body weight gain and adiposity 
through a stimulation of food intake while decreasing 
energy expenditure and body fat utilization [14]. 
Endocrine Effects 
Among central effects the most prominent are appetite 
stimulation and stimulation of growth hormone release. 
Actually, ghrelin provides at the same time GH release 
and calories that GH needs for growth and repair.  
GH releasing activity results from dual action, one syner-
gistic with GHRH and another through the inhibition of 
somatostatin. Ghrelin modulates lactotropic and cortico-
tropic activity, provoking ACTH, cortisol and PRL stimu-
lation. Additionally, it controls insulin secretion and influ-
ences thyroid function and reproduction [15,16]. 
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Metabolic actions of GH and ghrelin are comple-
mentary. GH stimulates protein synthesis, preserves car-
bohydrates and stimulates energy expenditure acting by 
favorizing lipolysis and fatty acids oxidation in calories 
replete, fed state. In starvation ghrelin levels are high, act-
ing as stimulator of energy intake and inhibitor of energy 
expenditure, and, at the same time, spending calories from 
carbohydrate intake. Additionally it stimulates glucose 
output by hepatocytes. 
Although a potent GH releasing agent ghrelin is not 
necessary for longitudinal growth. Namely ghrelin knock-
out mouse unexpectedly grows with normal velocity, 
reflecting thus the complexity of the regulation of GH 
system. The phenotype of ghrelin knock-out mouse 
includes normal size, growth rate, food intake, body 
composition, reproduction, and gross behavior, without 
any pathological changes. It could be explained by the fact 
that survival is more threatened by starvation than 
obesity [2]. 
However, the ghrelin-null mouse showed a significant 
reduction in body fat mass when the animal was fed with 
the high fat diet. Thus it is interesting to explore ghrelin 
level in idiopathic short stature [5,16,17]. 
Ghrelin, Endocrine Pancreas, Glucose  
and Lipid Metabolism  
Endocrine pancreas is the main source of the ghrelin 
during fetal life. Acylated and non acylated forms show 
opposite effect on glucose metabolism. Obestatin exhibits 
counter effect from acylated form. Ghrelin modulates 
both, exocrine and endocrine pancreatic functions. In-
sulin level is reduced, but glucagon level remains un-
changed [3, 5]. It is expressed in pancreatic cells and 
inhibits insulin release in mice, rats and humans. Abla-
tion of ghrelin, GHsR or GOAT enhances insulin release. 
This insulin static action of ghrelin/GHsR system could 
optimize the amount of insulin release on systemic de-
mand. The ghrelin blockade counteracts the obesity 
associated glucose intolerance in both, the life style-
related and genetic obese models. 
In healthy humans, total ghrelin levels are negatively 
associated with skeletal muscle mass , the fact that 
suggest a detrimental role on insulin sensitivity explored 
in human, animal and cellular models [15]. 
Effects on adipose tissue could shortly be summarized 
as following: adypogenic effect, lipolysis inhibition, 
influence on adipocyte proliferation, differentiation and 
apoptosis, regulating total number of adipocytes. The 
signalization is through MAPK and PI3K/Akt. 
Ghrelin as Link between Energy Balance 
and Fertility 
Ghrelin is more than orexigenic signal and GH secreta-
gogue. It influences gonadal axis and the onset of pu-
berty. It is well known that puberty onset and reproduction 
are metabolically gated. Conditions of starvation are asso-
ciated with perturbations in the timing of puberty and sub-
fertility. Thus ghrelin which operates as a signal of energy 
insufficiency and functional antagonist of leptin, may 
play a physiological and eventual pathophysiological role 
in the regulation of puberty onset and gonadal function 
[17]. Ghrelin receptors are identified in Leydig cells and 
follicular ovarian cells. It exerts inhibitory role on 
testosterone and LH secretion. PRL secretion is stimulated 
by ghrelin direct action on pituitary somatomammotroph 
cells. It is slight and dose-dependent PRL secretion. 
Ghrelin has been reported to exert an inhibitory effect on 
follicle-stimulating hormone, an, in particular, on 
luteinizing hormone, probably via an inhibitory effect 
exerted at the hypothalamic level on gonadotropin-
releasing hormone secretion [18].  
Ghrelin and Long Term Regulation  
of Energy Homeostasis 
Ghrelin is braking boundaries between short-term and 
long-term regulating signals in energy balancing. 
Modulatory effect of both forms of ghrelin, acylated and 
non acylated on adipogenesis is well documented. It has 
been shown that both forms of ghrelin directly promote 
adipogenesis in rat bone marrow adipocytes [19,20). 
Although the orexigenic action of ghrelin itself predicts 
impact on weight gain, ghrelin has also been shown to 
be able to directly act at the level of endocrine pancreas, 
liver and adipose tissue, thus modulating glucose and 
lipid metabolism [4,5,9]. Plasma levels of ghrelin are 
generally negatively correlated with body weight and 
increase in response to fasting with a subsequent decrease 
upon refeeding. In humans, ghrelin concentrations 
progressively decrease during childhood and adolescence, 
as well as with advancing puberty. In adolescents, 
similar to adults, ghrelin concentrations are inversely 
related to BMI and to circulating insulin [2124]. One 
notable exception is the presence of elevated ghrelin 
concentrations in subjects with Prader-Willi syndrome, 
raising the possibility that ghrelin could be part of the 
etiology of excess food intake in this condition [25]. 
Due to ghrelin’s ability to promote body weight gain 
and adiposity via centrally mediated signaling mecha-
nisms, modulation of the endogenous ghrelin system is 
considered a promising strategy to treat individuals with 
pathologically reduced body weight. 
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Ghrelin and Sepsis 
Even in modern Intensive Care Units (ICU), sepsis is 
the leading cause of mortality. Sepsis is characterized 
by hemodynamic perturbation as well as excessive pro-
duction of proinflammatory cytokines resulting in mul-
tiple organ dysfunction. Acute kidney injury (AKI) in 
septic patients increases the mortality to 50-80%. There-
fore it is of survival importance to identify potential ther-
apeutic interventions with the capability to attenuate sep-
sis related acute renal insufficiency. Ghrelin inhibits 
proinflammatory cytokine release (IL-1, IL-6 and TNF-
alfa) as well as endotheline activity responsible for 
vascular perfusion. Ghrelin improves tissue perfusion in 
severe sepsis via downregulation of endothelin-1. Gram- 
negative bacteria endotoxin is known to cause most of 
hemodynamic and inflammatory responses [2629]. In 
addition to any hemodynamic benefit of ghrelin in 
protecting against endotoxin-induced AKI, the agent’s 
anti-inflammatory properties are no doubt critical. There 
are experimental data that ghrelin protects against ex-
perimental sepsis by inhibiting High-Mobility Group 
Box 1 (HMGB1) release and by killing bacteria. HMBG 
is secreted by activated monocytes and macrophages in 
humans and animals with sepsis and endotoxemia, act-
ing as late proinflammatory factor. In animal models of 
sepsis, ghrelin improved bacterial clearance in vivo and 
showed bactericidal properties in vitro [28). Thus, 
ghrelin emerges as a natural antimicrobial and anti-in-
flammatory peptide, widely distributed in all body tis-
sues and especially abundant in the proximity to physical 
barriers such as stomach, gut, and skin suggesting that one 
of its primary functions could be related to the control of 
innate immunity and response against infections [2931]. 
Ghrelin, an Addiction Hormone 
The essential goal of feeding is to provide calories and a 
diversity of nutrients. However, we do not eat only for 
energy, we also eat for pleasure. Almost all circulating 
gut peptides contribute to the control of food intake by 
signaling satiety. One important exception is ghrelin, 
the only orexigenic peptide hormone so far described. 
Ghrelin interacts with the brain reward pathways to 
increase food intake, alter food preference and enhance 
food reward, thus influencing hedonic feeding control 
[32,33]. 
Evidence is accumulating linking obesity as an envi-
ronmental risk factor to psychiatric disorders such as 
stress, anxiety and depression. Plasma ghrelin levels are 
enhanced under conditions of physiological stress and 
ghrelin has recently been suggested to play an important 
role in stress-induced food reward behavior. In addition, 
chronic stress or atypical depression has often demon-
strated to correlate with an increase in ingestion of ca-
loric dense foods [34,35]. Recent evidence suggests ghrelin 
as a critical factor at the interface of homeostatic control of 
appetite and reward circuitries, modulating the hedonic 
aspects of food intake. Therefore, the reward-related 
feeding of ghrelin may reveal itself as an important 
factor in the development of addiction to certain foods, 
similar to its involvement in the dependence to drugs of 
abuse, including alcohol. Thus the ghrelinergic system 
could be an effective target for the development of suc-
cessful anti-obesity pharmacotherapies, which not only 
affects appetite but also selectively modulates the re-
warding properties of food and impact on psychological 
well-being in conditions of stress, anxiety and depres-
sion [3337]. 
Ghrelin and the Cardiovascular System 
The cardiovascular system has also been recognized as 
important target for ghrelin effects. A single injection of 
ghrelin provokes a significant decrease in blood pressure, 
without changing the heart rate, acting as antagonist of 
endothelin-1 [2,38]. In experimental models ghrelin 
showed cardioprotective effect against ischemia. Apart 
from vasodilatory effects, ghrelin may also have other 
vasoactive and anti-inflammatory properties and could be 
considered as therapeutic agent in conditions with athero-
sclerosis [39]. In hypophysectomized rats pretreated with 
GH secretagogues heart damage was prevented. Possible 
anti-apoptotic effects have also been studied on cardio-
myocytes and endothelial cells in vitro. In rats with 
experimental myocardial infarction, ghrelin treatment 
improved cardiac output [4042]. Chronic heart failure 
(CHF) remains one of the most challenging therapeutic 
problems, regarding frequency in ICU and high mortal-
ity rate, particularly so, if the CHF patient develops 
cardiac cachexia. Ghrelin and its analogs have been 
suggested to improve body weight and cardiac function 
in heart failure models [43]. 
In whom to Determine Ghrelin? 
Taking into account all above it is of practical importance 
to suggest in whom to investigate circulating ghrelin levels. 
In our opinion it is crucial to determine ghrelin or 
ghrelin/leptin ratio in lean subjects with abundant intake of 
energy dense food, searching for clue in achieving healthy 
balance in orexitropic signaling [44]. Obese and cachectic 
subjects are also candidates in order to rule out possible 
resistance syndromes as well as in addiction syndromes. 
With regard to children, SGA, IUGR neonates, septic 
children, patients with idiopathic short stature are cer-
tainly good candidates for ghrelin determination, being 
the population that deserves better understanding of their 
pathological conditions and opening new therapeutic 
approaches.  
Recently, we have found an important difference in 
appetite targeting hormones, ghrelin and leptin, and 
their profiles in a study group that included 88 children 
and adolescents aged 6 to17.67 years, classified as obese 
(30 subjects), undernourished (25 subjects) and lean (33 
subjects). Two orexitropic hormones showed different 
profiles in 3 different nutritional conditions; an inverse 
relationship was discovered between study groups in 
ghrelin/leptin and leptin/ghrelin ratios (unpublished data). 
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Clinical Application of Ghrelin 
Due to its adipogenic, orexigenic and diabetogenic 
activities, ghrelin has emerged as an attractive target for 
the treatment of different pathological conditions (Tab. 
1). Unacylated ghrelin agonists in animal and human 
studies exerted improvement in post-prandial glucose 
and insulin sensitivity, as well in prevention of fat 
accumulation. GOAT inhibitors have potential to decrease 
plasma acylated ghrelin, consequently resulting in reduc-
tion of blood glucose and weight gain. AG antagonists and 
blockers in animal and human models decrease AG central 
activity assessed by inhibition of GH secretion [45]. 
Table 1 Clinical application of ghrelin 
UG control of PPG (45) 
GOAT inhibitors BM and BG reduction  (45) 
Ghrelin agonists GHD diagnosis (2,5) 
Ghrelin agonists AN treatment (47,48,50) 
 AIDS, Cardiac cachexia  (1,43,46) 
 Cancer cachexia (43,45,46) 
Ghrelin antagonists Obesity (45,46,49) 
 Prader –Willi Sy (25) 
Ghrelin analogs Gastroparesis (51) 
 Postoperative ileus (51) 
Ghrelin Sepsis (animals) (29,30,31) 
UG  Unacylated ghrelin, GOAT  ghrelin O  acyltransferase 
enzyme, PPG  postprandial glucose, AN  Anorexia nervosa 
Ghrelin offers great potential for clinical application 
in diagnosis of pituitary function in GH deficiency, in 
eating disorders like anorexia and bulimia nervosa as 
well as in Prader-Willi syndrome, gastrointestinal diseases,  
cardiovascular disease (heart failure and dilated cardiomy-
opathy), osteoporosis, in aging, in catabolic state or chronic 
wasting syndrome, in cachexia (cancer and cardiac ca-
chexia), AIDS, postoperative patients [1,43,46]. Ana-
morelin, an oral ghrelin receptor agonist with appetite en-
hancing and anabolic activity is recently successfully 
applied in anorexia-cachexia syndrome [47,48]. 
At present, ghrelin is a unique peripheral orexigenic 
signal that is effective upon its intravenous injection. Thus 
blocking or neutralizing ghrelin’s action may be a reasona-
ble approach to reversing a chronic obesity [46,49].  
In Japan, ghrelin receptor agonist is clinically used 
as diagnostic agent for growth hormone secretion defi-
ciency. Recently, it has also been used as therapeutic agent 
in patients with severe form of anorexia nervosa. One-year 
intra-nasal application of such agonist in a severely ema-
ciated AN patient improved hypoglycemia and body 
weight [50]. 
Repeated administration of ghrelin can stimulate ap-
petite in patients with functional dyspepsia. Ghrelin also 
accelerates gastric emptying in diabetic gastroparesis and 
postoperative ileus after partial colectomy. Therefore, 
ghrelin analogs could represent a new class of prokinetic 
agents in the future [51]. However, most ghrelin com-
pounds are peptides and need to be injected several times 
per day, which affects the quality of life of patients in hu-
man clinical studies. 
Ghrelin, ghrelin agonists, receptor antagonists and 
reverse agonists are certainly potential diagnostic and 
therapeutic options for the future. 
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